BOUL Stock Overview
Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics.
Boule Diagnostics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr36.70|
|52 Week High||kr61.90|
|52 Week Low||kr32.10|
|1 Month Change||-0.54%|
|3 Month Change||-22.25%|
|1 Year Change||-35.73%|
|3 Year Change||-29.69%|
|5 Year Change||-51.87%|
|Change since IPO||213.01%|
Recent News & Updates
|BOUL||SE Medical Equipment||SE Market|
Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned -34.4% over the past year.
Return vs Market: BOUL underperformed the Swedish Market which returned -20.9% over the past year.
|BOUL Average Weekly Movement||5.6%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||7.4%|
|10% most volatile stocks in SE Market||12.2%|
|10% least volatile stocks in SE Market||4.7%|
Stable Share Price: BOUL is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BOUL's weekly volatility (6%) has been stable over the past year.
About the Company
Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally.
Boule Diagnostics Fundamentals Summary
|BOUL fundamental statistics|
Is BOUL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BOUL income statement (TTM)|
|Cost of Revenue||kr284.41m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 18, 2022
|Earnings per share (EPS)||1.42|
|Net Profit Margin||5.57%|
How did BOUL perform over the long term?See historical performance and comparison
1.5%Current Dividend Yield
Is BOUL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 6/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BOUL?
Other financial metrics that can be useful for relative valuation.
|What is BOUL's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does BOUL's PE Ratio compare to its peers?
|BOUL PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ADDV A ADDvise Group
CRAD B C-Rad
INTEG B Integrum
BOUL Boule Diagnostics
Price-To-Earnings vs Peers: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the peer average (872x).
Price to Earnings Ratio vs Industry
How does BOUL's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the Swedish Medical Equipment industry average (35.2x)
Price to Earnings Ratio vs Fair Ratio
What is BOUL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||25.8x|
|Fair PE Ratio||36.6x|
Price-To-Earnings vs Fair Ratio: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).
Share Price vs Fair Value
What is the Fair Price of BOUL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BOUL (SEK36.7) is trading below our estimate of fair value (SEK80.42)
Significantly Below Fair Value: BOUL is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: BOUL is good value based on its PEG Ratio (0.8x)
Discover undervalued companies
How is Boule Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOUL's forecast earnings growth (31% per year) is above the savings rate (0.3%).
Earnings vs Market: BOUL's earnings (31% per year) are forecast to grow faster than the Swedish market (9.7% per year).
High Growth Earnings: BOUL's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BOUL's revenue (7% per year) is forecast to grow faster than the Swedish market (5.6% per year).
High Growth Revenue: BOUL's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BOUL's Return on Equity is forecast to be low in 3 years time (15.8%).
Discover growth companies
How has Boule Diagnostics performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOUL has high quality earnings.
Growing Profit Margin: BOUL became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BOUL's earnings have declined by 38.3% per year over the past 5 years.
Accelerating Growth: BOUL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BOUL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).
Return on Equity
High ROE: BOUL's Return on Equity (9.1%) is considered low.
Discover strong past performing companies
How is Boule Diagnostics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BOUL's short term assets (SEK258.8M) exceed its short term liabilities (SEK239.4M).
Long Term Liabilities: BOUL's short term assets (SEK258.8M) exceed its long term liabilities (SEK66.3M).
Debt to Equity History and Analysis
Debt Level: BOUL's net debt to equity ratio (37.4%) is considered satisfactory.
Reducing Debt: BOUL's debt to equity ratio has increased from 24.6% to 49.3% over the past 5 years.
Debt Coverage: BOUL's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: BOUL's interest payments on its debt are well covered by EBIT (8.7x coverage).
Discover healthy companies
What is Boule Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BOUL's dividend (1.5%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.6%).
High Dividend: BOUL's dividend (1.5%) is low compared to the top 25% of dividend payers in the Swedish market (5.26%).
Stability and Growth of Payments
Stable Dividend: BOUL has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: BOUL's dividend payments have increased, but the company has only paid a dividend for 9 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (40.8%), BOUL's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: BOUL is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jesper Söderqvist (55 yo)
Mr. Jesper Söderqvist, Ph D., served as Director at Arcoma AB since June 2020 until May 2022 and Board Member and Chief Executive Officer of Dekatria AB. He served as Chief Executive Officer of Arcoma AB u...
CEO Compensation Analysis
Compensation vs Market: Jesper's total compensation ($USD389.26K) is above average for companies of similar size in the Swedish market ($USD232.52K).
Compensation vs Earnings: Jesper's compensation has been consistent with company performance over the past year.
Experienced Management: BOUL's management team is considered experienced (2.3 years average tenure).
Experienced Board: BOUL's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boule Diagnostics AB (publ)'s employee growth, exchange listings and data sources
- Name: Boule Diagnostics AB (publ)
- Ticker: BOUL
- Exchange: OM
- Founded: 1956
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: kr712.587m
- Shares outstanding: 19.42m
- Website: https://www.boule.com
Number of Employees
- Boule Diagnostics AB (publ)
- Domnarvsgatan 4
- Stockholm County
- 163 53
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.